Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

$15

$14 to $18Selected Income Statement Guidance ($ in millions)Item

2011 Guidance

Previous 2011 GuidanceCost of Sales (% of Total Revenue)

Unchanged

18% to 20%Selling, General and Admin. Expense

Unchanged

$164 to $174Research and Development Expense

$200 to $205

$195 to $205Amortization and Contingent Consideration

$2

$15Interest Income

Unchanged

$3Income Tax Expense (Benefit)

$14

$15GAAP Net Income (Loss)

$(43) to $(33)

$(52) to $(42)Stock Compensation Expense

$45

$43Non-GAAP Adjusted EBITDA

$49 to $59

$51 to $61Anticipated Upcoming Milestones3Q 2011/4Q 2011: Top-line results for Phase II trial for PEG-PAL, including daily dosing and formulation studies
1Q 2012/2Q 2012: Initiation of Phase III trial for PEG-PAL
1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia
2H 2012: Top-line results for Phase III trial for GALNS for MPS IVA
2H 2012: Top-line results for PKU-016 Kuvan neurocognitive study
2H 2012: Top-line results for Phase I/II trial for BMN-701 for Pompe disease
4Q 2012/1Q 2013: Market authorization application filings for GALNS for MPS IVA
1Q 2013-3Q 2013: 510k clearance and commercial availability of the handheld blood Phe monitor for PKU

Research and Development ProgramsBioMarin continues to make significant investments in research and development to ensure persistent growth of the company.  The current pipeline includes programs in various stages of development that are focused on treating a range of serious unmet medical needs.Advanced Clinical Programs

  • GALNS for MPS IVA: BioMarin is enrolling patients in the randomized, double-blind, placebo-controlled Phase III study with primary endpoint of six-minute walk distance, 24 weeks in treatment duration and treatment doses of two mg/kg/week and two mg/kg/every other week.  The company exp
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2015)... April 20, 2015 Pharmaceutical Research and Manufacturers ... billion last year in the research and development (R&D) ... the majority of all biopharmaceutical R&D spending – both ... States . The new R&D numbers, the result ... highlighted in the newly released PhRMA 2015 ...
    (Date:4/20/2015)...  Purdue Pharma, a leading specialty pharmaceutical company, ... joined the company as Senior Vice President of ... for all of Purdue,s efforts to acquire or ... benefit from our patient-focused commercial capabilities. ... President & CEO Mark Timney . "Alan ...
    (Date:4/20/2015)... LINCOLNSHIRE, Ill. , April 20, 2015  U.S. pharmacy ... are expected to drift into the low double-digits by 2016, ... global talent, retirement and health solutions business of Aon ... plan design changes are projected to be 9.5 percent in ... 2016. Aon Hewitt predicts a similar rate of ...
    Breaking Medicine Technology:PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4
    ... Corp. (NASDAQ: KOOL ), a leading supplier of ... cells, said today that Mahendra Rao, M.D., Ph.D. has resigned ... Rao has been appointed to a position with the National ... a director of the Company, pursuant to NIH and federal ...
    ... 1, 2011 Merrimack Pharmaceuticals, Inc. announced today ... has granted MM-398 orphan drug status for the ... stable nanotherapeutic encapsulation of the marketed chemotherapy drug ... development and commercialization in Taiwan under the designation ...
    Cached Medicine Technology:ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 2ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 3FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2
    (Date:4/21/2015)... 2015 CALNOC, the nation’s first nursing ... RN, FAAN, will keynote their upcoming conference – Navigating ... CA on October 26, 2015. , Dr. Burnes ... of Nurse Executives (AONE) and the first African American ... American Academy of Nursing and the National Black Nurses ...
    (Date:4/21/2015)... Renewable energy, sustainable living, the greening of ... Day topics USM Studios ’ programming covers in ... affect of climate change on the planet, the award-winning ... on the environmental concerns affecting the nation and world ... lifestyles, clean air options, and much more when the ...
    (Date:4/21/2015)... TX (PRWEB) April 21, 2015 ... from a prestigious Illinois university for a second ... units (NICUs) more conducive to newborn infants’ cognitive ... top three NICU problems we have identified through ... care professionals,” said George Hutchinson, Invictus Medical’s Chief ...
    (Date:4/20/2015)... (PRWEB) April 20, 2015 Heritage Woods ... host an Open House and Dine-and-Dash Spaghetti Dinner from ... The community, which is located in Centralia, Illinois, houses ... homes for low-income adults 55 and older. , Guests ... staff about supportive living options for seniors. After the ...
    (Date:4/20/2015)... 21, 2015 Reality show stars, food, ... at the twentieth annual Michigan International Women’s Show, April ... , “There is lots to see and do from ... for fashion and gifts,” said Beth Anderson, executive show ... and encouraging with appearances from Randy Fenoli of ‘Say ...
    Breaking Medicine News(10 mins):Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3
    ... Behen HealthDay Reporter , FRIDAY, Jan. 20 (HealthDay ... good job of informing American women with early stage breast ... surgery, a new study suggests. In the study, researchers ... on their knowledge of the disease. Respondents typically answered only ...
    ... Quitting smoking is never easy. However, when you,re poor ... hard, according to a new study by a tobacco ... (CCNY). Christine Sheffer, associate medical professor at CCNY,s ... different socioeconomic backgrounds after they had completed a statewide ...
    ... The Mount Sinai Medical Center in New York have ... known as phthalates and obesity in young children ... Phthalates are man-made, endocrine-disrupting chemicals that can ... in plastic flooring and wall coverings, food processing materials, ...
    ... ON When cancers become aggressive and spread they ... how to stop this development. A new imaging platform ... and John Lewis is providing insight into just that ... Certain proteins, such as E-cadherin, are important for ...
    ... per cent of patients hospitalized after a stroke develop delirium, ... Researchers found patients who experience delirium after stroke are five ... be discharged to a long-term care facility, nursing home or ... and prevention of delirium are important for a quick recovery, ...
    ... are the Robinson Crusoes of the intracellular world -- ... where their fellow chromosomes reside. Such castaways, each confined ... cells, but scientists haven,t known what role, if any, ... paper published online on Jan. 18 by the journal ...
    Cached Medicine News:Health News:Many Breast Cancer Patients Uninformed About Options: Study 2Health News:Many Breast Cancer Patients Uninformed About Options: Study 3Health News:Poorest smokers face toughest odds for kicking the habit 2Health News:Exposure to chemical found in personal care products may contribute to childhood obesity 2Health News:Lawson researchers engineer a switch to tame aggressive cancers 2Health News:Study finds delirium after stroke linked to poorer outcomes for patients 2Health News:'Pulverized' chromosomes linked to cancer? 2Health News:'Pulverized' chromosomes linked to cancer? 3
    ... design allows "Four gels in one tank" electrophoresis. ... run 200 samples or more in one compact ... gels. To ensure even migration, the electrode height ... being run. Ideal for high throughput procedures, an ...
    ... tanks come with turn and cast gel ... pouring as simple as possible. , ... your application. Avaialble in a variety of ... gel size right up to the 20 ...
    ... UniPhor units can be used for: ... and non denaturing SDS-PAGE gels IEF ... Z64,075 1) Preparative Protein and Peptide ... gels IEF in Agarose Ampholyte Gels ...
    ... Horizontal Gel System provides a compact format ... DNA fragments, PCR products and synthetic oligonucleotides, ... The Mini Horizontal Unit has gel bed ... The gel bed is UV transparent. Adjustable ...
    Medicine Products: